Antiplatelet drug market to face big transition

The domestic antiplatelet drugs market will undergo a major transformation as AstraZenca is set to launch its new platelet aggregation inhibitor Brilinta (ticagrelor) in the latter half of this year.

So far, Sanofi-Aventis’s Plavix (clopidogrel) kept its number 1 ranking in terms of revenue, but Brilinta is expected to get a bigger share due to better safety profiles.

A study published in...